inflammatory fasciitis throughout his left upper shoulder girdle; Musculoskeletal Sequelae; subjective cold sensation lasted 8 h; The initial case was missing the following minimum criteria: identifiable patient. Upon receipt of follow-up information on 22Jun2022, this case now contains all required information to be considered valid. Author reported 2 reports. This is 1 of 2.  Follow-up (22Jun2022): This is a literature report. This is a follow-up report based on the receipt of the publication; the case has been updated to include additional information identified in the publication:  A 48-year-old male patient received BNT162b2 (BNT162B2), in 2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "medication-controlled hypertension" (unspecified if ongoing); "Hyperlipidemia" (unspecified if ongoing); "sublingual salivary cyst excision" (unspecified if ongoing); "nasal septum surgery" (unspecified if ongoing); "severe pain" (unspecified if ongoing); "spasms throughout the left upper quarter of body" (unspecified if ongoing); "Non Smoker" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Rosuvastatin; Olmesartan. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 immunization. The following information was reported: MUSCULOSKELETAL DISORDER (non-serious) with onset 2021, 2 days after the suspect product(s) administration, outcome "recovered" (2021), described as "Musculoskeletal Sequelae"; FASCIITIS (hospitalization) with onset 2021, 2 days after the suspect product(s) administration, outcome "recovered" (2021), described as "inflammatory fasciitis throughout his left upper shoulder girdle"; FEELING COLD (non-serious) with onset 2021, 1 day after the suspect product(s) administration, outcome "recovered" (2021), described as "subjective cold sensation lasted 8 h". The patient was hospitalized for fasciitis (hospitalization duration: 4 day(s)). The patient underwent the following laboratory tests and procedures: Body mass index: 23.7; C-reactive protein: 4.34, notes: marked elevated; Full blood count: within reference range; Laboratory studies: Unknown result; Magnetic resonance imaging: showed inflammatory fasciitis throughout his left, notes: upper shoulder girdle, mild supraspinatus tendinitis, and enlarged cervical nodes; Pyrexia: 101.3, notes: Fahrenheit; Red blood cell sedimentation rate: within reference range; Rheumatological examination: within reference range; Ultrasound chest: ultrasound revealed a fluid collection in the SC, notes: joint; Musculoskeletal ultrasound of the sternoclavicular, notes: joint showing slight swelling and fluid collection; X-ray: did not have any remarkable findings. Therapeutic measures were taken as a result of fasciitis, musculoskeletal disorder.; Sender's Comments: Based on the available reported information, the causal association between the events and the suspect drug BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.